Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Li, Zhongkang; Zhang, Mingle; Tian, Yanpeng; Li, Qian; Huang, Xianghua

doi:10.3389/fcell.2021.718192

Cited by 32 publications

(31 citation statements)

References 141 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of MSCs in the treatment of reproductive system diseases has been confirmed by preclinical and clinical research, which has brought great hope to POF infertility and improved female reproductive health (Herraiz et al, 2019;Fu et al, 2021;Li et al, 2021). MSCs used for the treatment of POF include BMSCs, UCMSCs, PMSCs, AMSCs, AFMSCs, MenSCs and ADMSCs.…”

Section: Mscs and Fertility Protectionmentioning

confidence: 97%

Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review

Wang

Liu

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Premature ovarian failure (POF) has become one of the main causes of infertility in women of childbearing age and the incidence of POF is increasing year by year, seriously affecting the physical and mental health of patients and increasing the economic burden on families and society as a whole. The etiology and pathogenesis of POF are complex and not very clear at present. Currently, hormone replacement therapy is mainly used to improve the symptoms of low estrogen, but cannot fundamentally solve the fertility problem. In recent years, stem cell (SC) transplantation has become one of the research hotspots in the treatment of POF. The results from animal experiments bring hope for the recovery of ovarian function and fertility in patients with POF. In this article, we searched the published literature between 2000 and 2020 from the PubMed database (https://pubmed.ncbi.nlm.nih.gov), and summarized the preclinical research data and possible therapeutic mechanism of mesenchymal stem cells (MSCs) in the treatment of POF. Our aim is to provide useful information for understanding POF and reference for follow-up research and treatment of POF.

show abstract

Section: Mscs and Fertility Protectionmentioning

confidence: 97%

Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review

Wang

Liu

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…As to premature ovarian insufficiency (POI), an intractable endocrine disease that severely restricts the reproductive and physiological function of females and resultant in menopausal symptoms, a series of literatures have suggested the ameliorative effect of hydrogel/MSC composite or hydrogel/MSC-derived microvesicles/secretomes via facilitating angiogenesis, enhancing granulosa cell generation and steroidogenesis, and accelerating follicular regeneration [98][99][100][101]. Notably, Li et al have summarized the current renewal of the therapeutic effects and molecular mechanisms of MSCbased cytotherapy in both preclinical research and clinical trials [102].…”

Section: Hydrogels/mscs Scaffolds For Reproductive Diseasesmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells and Hydrogel Scaffolds for Tissue Engineering

Zhang¹,

Han²

2023

Hydrogels - From Tradition to Innovative Platforms With Multiple Applications

View full text Add to dashboard Cite

Hydrogels are splendid biomaterials and play a critical role in multiple applications for disease management via offering a microenvironment for drug metabolism and exerting the bonding effect attribute to the preferable physical and chemical properties. State-of-the-art renewal has indicated the combination of hydrogels with mesenchymal stem/stromal cells (MSCs), which are heterogeneous populations with unique hematopoietic-supporting and immunoregulatory properties. For decades, we and other investigators have demonstrated the promising prospects of MSCs in regenerative medicine, and in particular, for the administration of recurrent and refractory disease. Very recently, we took advantage of the hydrogel/MSC composite for the applications in osteoarthritis, burn wounds, and refractory wounds associated with diabetic foot as well. Strikingly, the composite showed superiority in continuous improvement of the biological functions of the injured areas over hydrogels or MSCs, respectively. Collectively, hydrogel-based biomaterials are of importance for disease treatment and the accompanied regenerative medicine. Therefore, in this chapter, we will summarize the latest updates of hydrogel/MSCs composite in tissue engineering and put forward the direction of hotspot issues in the future including hydrogel/MSC and hydrogel/MSC-exosome in preclinical and clinical studies.

show abstract

“…Relying on the natural abilities of stem cells, researchers have used their biological mechanisms for stem-cell-based therapy. The mechanisms of action through which stem cells can promote the regeneration of tissue are diverse, including (1) inhibition of inflammation cascades [ 18 , 19 ], (2) reduction of apoptosis [ 20 , 21 ], (3) cell recruitment [ 22 , 23 ], (4) stimulation of angiogenesis [ 24 , 25 ], and (5) differentiation [ 26 ]. The cause of a disease is a vital consideration in selecting the proper stem cell mechanism and in the regeneration of tissue/organs using stem cells.…”

Section: Introductionmentioning

confidence: 99%

Stem Cell Therapy: From Idea to Clinical Practice

Ghasroldasht

Seok

Park

et al. 2022

IJMS

View full text Add to dashboard Cite

Regenerative medicine is a new and promising mode of therapy for patients who have limited or no other options for the treatment of their illness. Due to their pleotropic therapeutic potential through the inhibition of inflammation or apoptosis, cell recruitment, stimulation of angiogenesis, and differentiation, stem cells present a novel and effective approach to several challenging human diseases. In recent years, encouraging findings in preclinical studies have paved the way for many clinical trials using stem cells for the treatment of various diseases. The translation of these new therapeutic products from the laboratory to the market is conducted under highly defined regulations and directives provided by competent regulatory authorities. This review seeks to familiarize the reader with the process of translation from an idea to clinical practice, in the context of stem cell products. We address some required guidelines for clinical trial approval, including regulations and directives presented by the Food and Drug Administration (FDA) of the United States, as well as those of the European Medicine Agency (EMA). Moreover, we review, summarize, and discuss regenerative medicine clinical trial studies registered on the Clinicaltrials.gov website.

show abstract

Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Cited by 32 publications

References 141 publications

Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review

Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review

Mesenchymal Stem/Stromal Cells and Hydrogel Scaffolds for Tissue Engineering

Stem Cell Therapy: From Idea to Clinical Practice

Contact Info

Product

Resources

About